The US Department of Justice (DOJ) recently issued a final order (the Order) immediately rescheduling certain marijuana-related products from ...

Tilray Brands’ fair value estimate currently stands at $10.04, with the latest update keeping this price target unchanged. Even with several analysts trimming their targets in both US$ and C$, others ...

Recent moves by the Trump Administration could lead to cheaper medicinal cannabis and the ability for those who use it to ...

Alexander Malyshev and Sarah Ganley of Carter Ledyard & Milburn LLP explain the approach and significance of the final order ...

Members of Congress joined activists at a press conference on Wednesday to highlight the need for further federal marijuana ...

Despite years of moves to loosen marijuana restrictions, pot is still illegal at the federal level (with some new exceptions) ...

When the acting attorney general moved state-licensed medical marijuana and FDA-approved marijuana-containing products from ...

Rescheduling does matter greatly. Moving from Schedule I to Schedule III takes marijuana out of the same league as heroin, ...

The move also essentially splits the cannabis market in states that have legalized weed for both medical and recreational consumers.

These companies are major players in the U.S. marijuana market, and they all generated more than $1 billion in revenue last year.

Researchers at Johns Hopkins and UC San Diego used artificial intelligence to analyze comments in the public record ...

President Trump has signed an executive order reclassifying marijuana as *** less dangerous drug, so this move could ease regulations now and could change taxation too. Our Washington correspondent ...